Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI;Irbesartan y enfermedad renal crónica avanzada de causa no diabética. Estudio comparativo con IECAS

Nefrologia

Volumn 28, Issue 1, 2008, Pages 56-60

  Coronel, Francisco ^a   Cigarran S ^b   Garcia Mena M ^a   Herrero, J A ^a   Calvo, N ^a   Perez Flores I ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Chronic kidney disease; Hypertension; Irbesartan; Proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 47049096598     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde Rd. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Eng J Med 329: 1456-62, 1993.
2. Lebovitz HE, Wiegmann TB, Cnaan A, Shainfar S, Sica DA, Broadstone V y cols. Renal protective effect of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 45 (Supl.): S150-55, 1994.
3. Ihle BU, Whitworth JA, Shainfar S, Cnaan A, Kinkaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal inssufiency: a controlled double-blind trial. Am J Kidney Dis 27: 489-95, 1996.
4. The GISEN group (Gruppo Italiano di Studi Epidemiologici in nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-63, 1997.
5. Jafar TH, Schmid CH, Ianda M, Giatras I, Toto R, Remuzzi G, for the ACE Inhibition in Progressive Renal Disease Study Group: angiotensin-coverting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135: 73-87, 2001.
6. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289: 2560-72, 2003.
7. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med 345: 870-78, 2001.
8. Bakris GL, Weir MR : Angiotensin-converting enzyme inhibitor -associated elevations in serum creatinine: Is the cause for concern? Ann Intern Med 160: 685-693, 2000.
9. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357: 1601-1608, 2001.
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH y cols. Effects of losartan on renal and cardiovascular outcomes in patients in patients with type 2 diabetes and nephropathy. N Eng J Med 345: 861-69, 2001.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB y cols. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345: 851-60, 2001.
12. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction with Valsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106: 672-78, 2002.
13. Plum J, Bunten B, Nemeth R, Grabensee B. Effect of the angiotensin II antagonist valsartan on blood pressure, proteinuria and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 9: 2223-34, 1998.
14. Praga M, Fernández-Andrade C, Luño J, Arias M, Poveda R, Mora J y cols. Antiproteinuric efficacy of losartan in comparison with amlodipine in nondiabetic proteinuric renal disease: a double-blind, randomized clinical trial. Nephrol Dial Transplant 18: 1806-13, 2003.
15. De Rosa ML, De Cristofaro A, Rossi M, Baiano A, Cardace P, Albanese L, Vigorito C. Irbesartan effect on renal function in patients with renal impairment and hipertension: a drug withdrawal study. J Cardiovasc Pharmacol 38: 482-89, 2001.
16. Sharma AM, Hollander A, Köster J: Efficacy and Safety in Patients with Renal Impairment treated with telmisartan (ESPRIT) Study Group. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 63: 250-57, 2005.
17. Coronel F, Ruiz E, Herrero JA, Martín P, Mateos P, Touchard A y cols. Effect of an angiotensin receptor antagonist (irbesartan) on peritoneal dialysis patients. Perit Dial Int 20 (Supl. 1): S62, 2000.
18. Burnier M, Brunner HR. Angiotensin II receptor antagonist in hypertension. Kidney Int 54 (Supl. 68): S107-S111, 1998.
19. Gillis JC, Markam A. Irbesartan. A review of its pharmacodynamic properties and therapeutic use in the management of hypertension. Drugs 54: 885-902, 1997.
20. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C y cols. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42: 452-58, 1992.
21. Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K y cols. Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators. Interim evidence of the renoprotective effect of the angiotensina II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Renal Global Protection in Hypertensive Patients (JLIGHT) Study. Clin Exp Nephrol 7: 221-30, 2003.
22. Bakris GL, Siomos M, Richardson D, Jannsen I, Bolton WK, Hebert L y cols. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 58: 2084-92, 2000.
23. Weinberg AJ, Zappe DH, Ashton M, Weinberg MS. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease. A pilot study. Am J Nephrol 24: 340-45, 2004.
24. Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H y cols. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 41: 793-97, 2002.
25. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 19: 1855-60, 2002.
26. Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens Supl. 20: S29-31, 2002.